Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL

M van Gelder¹, O Tournilhac², D Te Raa³, H P J Visser⁴

Affiliations

¹ Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands. Electronic address: m.van.gelder@mumc.nl.
² Service for Cell Therapy and Clinic for Hematology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
³ Department of Internal Medicine, Gelderse Vallei Hospital, Ede, the Netherlands.
⁴ Northwest Oncology Center, Northwest Hospital Group, Alkmaar, the Netherlands.

PMID: 34428511
DOI: 10.1016/j.annonc.2021.08.1990

Free article

Comment

Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL

M van Gelder et al. Ann Oncol. 2021 Nov.

Free article

. 2021 Nov;32(11):1442-1443.

doi: 10.1016/j.annonc.2021.08.1990. Epub 2021 Aug 21.

Authors

M van Gelder¹, O Tournilhac², D Te Raa³, H P J Visser⁴

Affiliations

¹ Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands. Electronic address: m.van.gelder@mumc.nl.
² Service for Cell Therapy and Clinic for Hematology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
³ Department of Internal Medicine, Gelderse Vallei Hospital, Ede, the Netherlands.
⁴ Northwest Oncology Center, Northwest Hospital Group, Alkmaar, the Netherlands.

PMID: 34428511
DOI: 10.1016/j.annonc.2021.08.1990

No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have declared no conflicts of interest.

Comment on

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Eichhorst B, et al. Ann Oncol. 2021 Jan;32(1):23-33. doi: 10.1016/j.annonc.2020.09.019. Epub 2020 Oct 19. Ann Oncol. 2021. PMID: 33091559 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL

Affiliations

Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources